Which diabetes drug is better for kidneys in advanced kidney disease?
Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at two common diabetes drugs to see which one protects the kidneys and heart better in people with very bad kidney disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 555 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at two common diabetes drugs to see which one protects the kidneys and heart better in people with very bad kidney disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 555 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Publication
Authors
Chen JJ, Tsai MH, Ho WY, Fang YW, Chen MT, Hsiao CC
Related Content
Claims (7)
GLP-1 receptor agonists lower the risk of heart and kidney complications in people with type 2 diabetes and chronic kidney disease by directly activating GLP-1 receptors, regardless of changes in body weight or use of mineralocorticoid receptor antagonists.
In adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor is linked to a 6% lower chance of developing heart failure than starting a GLP-1 receptor agonist, while the chances of major heart problems or death are the same with either drug.
Among adults with type 2 diabetes and advanced kidney disease, starting a GLP-1 receptor agonist is linked to a higher rate of serious kidney complications than starting an SGLT2 inhibitor, and this difference is larger in men and in people who do not already have heart failure.
Among adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor instead of a GLP-1 receptor agonist is linked to a 5% lower risk of serious kidney complications, a 9% higher risk of needing dialysis, and no difference in heart events or death rates.
Among adults with type 2 diabetes and advanced kidney disease, starting an SGLT2 inhibitor is linked to a 6% lower risk of heart failure than starting a GLP-1 receptor agonist, while the risks of major heart problems and death are the same with both drugs.